|  |  |  |  |
| --- | --- | --- | --- |
| **Порядковый номер ссылки** | **Авторы, название публикации и источника, где она опубликована, выходные данные** | **ФИО, название публикации и источника на английском** | **Полный интернет-адрес (URL) цитируемой статьи или ее doi.** |
| 1 | Anagnostou A., Lee E.S., Kessimian N., Levinson R., Steiner M. [Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells.](https://www.ncbi.nlm.nih.gov/pubmed/2165612) *Proc. Natl. Acad. Sci. USAб 1990, Vol. 87, no. 15, pp. 5978-5982.* | *-.* |  |
| 2 | Bennis Y., Sarlon-Bartoli G., Guillet B., Hubert L., Pellegrini P., Velly L., Blot-Chabaud M., Dignat-Georges F., Sabatier F., Pisano P. Priming of late endothelial progenitor cells with erythropoietin before transplantation requires the CD131 receptor subunit and enhances their angiogenic potential. *J. Thromb. Haemost, 2012, Vol. 10, pp. 1914-1928.* | *-* |   |
| 3 | [Ercan E](https://www.ncbi.nlm.nih.gov/pubmed/?term=Ercan%20E%5BAuthor%5D&cauthor=true&cauthor_uid=24011510)., [Bagla A.G](https://www.ncbi.nlm.nih.gov/pubmed/?term=Bagla%20AG%5BAuthor%5D&cauthor=true&cauthor_uid=24011510)., [Aksoy A](https://www.ncbi.nlm.nih.gov/pubmed/?term=Aksoy%20A%5BAuthor%5D&cauthor=true&cauthor_uid=24011510)., [Gacar G](https://www.ncbi.nlm.nih.gov/pubmed/?term=Gacar%20G%5BAuthor%5D&cauthor=true&cauthor_uid=24011510)., [Unal Z.S](https://www.ncbi.nlm.nih.gov/pubmed/?term=Unal%20ZS%5BAuthor%5D&cauthor=true&cauthor_uid=24011510)., [Asgun H.F](https://www.ncbi.nlm.nih.gov/pubmed/?term=Asgun%20HF%5BAuthor%5D&cauthor=true&cauthor_uid=24011510)., [Karaoz E](https://www.ncbi.nlm.nih.gov/pubmed/?term=Karaoz%20E%5BAuthor%5D&cauthor=true&cauthor_uid=24011510). In vitro protection of adipose tissue-derived mesenchymal stem cells by erythropoietin. [*Acta Histochem, 2014, Vol.*](https://www.ncbi.nlm.nih.gov/pubmed/24011510)*, 116, no. 1, pp. 117-125.* | *-* |   |
| 4 | Fisher S.A., Doree C., Brunskill S.J., Mathur A., Martin-Rendon E. Bone Marrow Stem Cell Treatment for Ischemic Heart Disease in Patients with No Option of Revascularization: A Systematic Review and Meta-Analysis. *PLoS ONE, 2013, Vol. 8, no. 6, e64669* | *-* | [[*https://doi.org/10.1371/journal.pone.006*](https://doi.org/10.1371/journal.pone.006)*.]* |
| 5 | George J., Goldstein E., Abashidze A., Wexler D., Hamed S., Shmilovich H., Deutsch V., Miller H., Keren G., Roth A. Erythropoietin promotes endothelial progenitor cell proliferative and adhesive properties in a PI 3-kinase-dependent manner. *Cardiovasc Res, 2005, Vol. 68, pp. 299-306.* | *-* |  |
| 6 | Heeschen C., Aicher A., Lehmann R., Fichtlscherer S., Vasa M., Urbich C., Mildner-Rihm C., Martin H., Zeiher A.M., Dimmeler S. [Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization.](https://www.ncbi.nlm.nih.gov/pubmed/12702503) *Blood, 2003, Vol. 102, no. 4, pp. 1340-1346.* | *-* |  |
| 7 | Henry T.D., Schaer G.L., Traverse J.H., Povsic T.J., Davidson C., Lee J.S., Costa M.A., Bass T., Mendelsohn F., Fortuin F.D., Pepine C.J., Patel A.N., Riedel N., Junge C., Hunt A., Kereiakes D.J., White C., Harrington R.A., Schatz R.A., Losordo D.W., and the ACT34-CMI Investigators. Autologous CD34+ Cell Therapy for Refractory Angina: 2-Year Outcomes from the ACT34-CMI Study. *Cell Transplant, 2016, Vol. 25, pp. 1701-1711.* | *-* |  |
| 8 | Hirata A., Minamino T., Asanuma H., Fujita M., Wakeno M., Myoishi M., Tsukamoto O., Okada K., Koyama H., Komamura K., Takashima S., Shinozaki Y., Mori H., Shiraga M., Kitakaze M., Hori M. Erythropoietin enhances neovascularization of ischemic myocardium and improves left ventricular dysfunction after myocardial infarction in dogs. *J. Am. Coll. Cardio, 2006, Vol. 48, pp 176-184.* | *-* |  |
| 9 | [Hu R](https://www.ncbi.nlm.nih.gov/pubmed/?term=Hu%20R%5BAuthor%5D&cauthor=true&cauthor_uid=25051281)., [Cheng Y](https://www.ncbi.nlm.nih.gov/pubmed/?term=Cheng%20Y%5BAuthor%5D&cauthor=true&cauthor_uid=25051281)., [Jing H](https://www.ncbi.nlm.nih.gov/pubmed/?term=Jing%20H%5BAuthor%5D&cauthor=true&cauthor_uid=25051281)., [Wu H](https://www.ncbi.nlm.nih.gov/pubmed/?term=Wu%20H%5BAuthor%5D&cauthor=true&cauthor_uid=25051281). Erythropoietin promotes the protective properties of transplanted endothelial progenitor cells against acute lung injury via PI3K/Akt pathway. [*Shock*](https://www.ncbi.nlm.nih.gov/pubmed/?term=Hu+R.%2C+Cheng+Y.%2C+Jing+H.%2C+Wu+H.++%2F%2F+Shock.+2014.+Vol.+42(4).+P.+327-336.)*, 2014, Vol. 42, no. 4, pp. 327-336.* | *-* |  |
| 10 | Jang J., Yun J.Y., Hur1J., Kang J.A., Choi J.I., Ko S.B., Lee J, Kim J.Y., Hwang I.C., Park Y.B., Kim H.S. Erythropoietin priming improves the vasculogenic potential of G-CSF mobilized human peripheral blood mononuclear cells. *Cardiovascular Res, 2014, Vol. 104, pp. 171-182.* | *-* |  |
| 11 | Kimakova P., Solar P., Solarova Z., Komel R., Debeljak N. Erythropoietin and Its Angiogenic Activity. *Int. J. Mol. Sci, 2017, Vol. 18, pp. 1519.* | *-* | [*DOI:10.3390/ijms18071519.]* |
| 12 | Lisowska K.A., Debska-Slizien A., Bryl E., Rutkowski B., Witkowski J.M. Erythropoietin receptor is expressed on human peripheral blood T and B lymphocytes and monocytes and is modulated by recombinant human erythropoietin treatment. *Artif Organs, 2010, V0l. 34, pp. 654-662.* | *-* |  |
| 13 | [Madigan M](https://www.ncbi.nlm.nih.gov/pubmed/?term=Madigan%20M%5BAuthor%5D&cauthor=true&cauthor_uid=29642402)., [Atoui R](https://www.ncbi.nlm.nih.gov/pubmed/?term=Atoui%20R%5BAuthor%5D&cauthor=true&cauthor_uid=29642402). Therapeutic Use of Stem Cells for Myocardial Infarction. [*Bioengineering (Basel), 2018, Vol. 5, no. 2.,*](https://www.ncbi.nlm.nih.gov/pubmed/29642402) *E28.* | *-* | [*DOI: 10.3390/bioengineering5020028.]* |
| 14 | Mozid A., Yeo C., Arnous S., Ako E., Saunders N., Locca D., Brookman P., Archbold R.A., Rothman M., Mills P., Agrawal S., Martin J., Mathur A. Safety and feasibility of intramyocardial versus intracoronary delivery of autologous cell therapy in advanced heart failure: the REGENERATE-IHD pilot study. *Regen. Med, 2014, Vol. 9, no. 3, pp. 269-278.* | *-* |  |
| 15 | [Pavo I.J](https://www.ncbi.nlm.nih.gov/pubmed/?term=Pavo%20IJ%5BAuthor%5D&cauthor=true&cauthor_uid=28289528)., [Michel-Behnke I](https://www.ncbi.nlm.nih.gov/pubmed/?term=Michel-Behnke%20I%5BAuthor%5D&cauthor=true&cauthor_uid=28289528). Clinical cardiac regenerative studies in children. [*World J. Cardio, 2017, Vol. 9, no. 2, pp.*](https://www.ncbi.nlm.nih.gov/pubmed/28289528) *147-153.* | *-* |  |
| 16 | [Rupp S](https://www.ncbi.nlm.nih.gov/pubmed/?term=Rupp%20S%5BAuthor%5D&cauthor=true&cauthor_uid=22329889)., [Jux C](https://www.ncbi.nlm.nih.gov/pubmed/?term=Jux%20C%5BAuthor%5D&cauthor=true&cauthor_uid=22329889)., Bonig H., [Bauer J](https://www.ncbi.nlm.nih.gov/pubmed/?term=Bauer%20J%5BAuthor%5D&cauthor=true&cauthor_uid=22329889)., [Tonn T](https://www.ncbi.nlm.nih.gov/pubmed/?term=Tonn%20T%5BAuthor%5D&cauthor=true&cauthor_uid=22329889)., [Seifried E](https://www.ncbi.nlm.nih.gov/pubmed/?term=Seifried%20E%5BAuthor%5D&cauthor=true&cauthor_uid=22329889)., [Dimmeler S](https://www.ncbi.nlm.nih.gov/pubmed/?term=Dimmeler%20S%5BAuthor%5D&cauthor=true&cauthor_uid=22329889)., [Zeiher A.M](https://www.ncbi.nlm.nih.gov/pubmed/?term=Zeiher%20AM%5BAuthor%5D&cauthor=true&cauthor_uid=22329889)., [Schranz D](https://www.ncbi.nlm.nih.gov/pubmed/?term=Schranz%20D%5BAuthor%5D&cauthor=true&cauthor_uid=22329889). Intracoronary bone marrow cell application for terminal heart failure in children. [*Cardiol. Young, 2012, Vol. 22, no. 5, pp.*](https://www.ncbi.nlm.nih.gov/pubmed/22329889) *558-563.* | *-* |  |
| 17 | Seurder D., Radrizzani M., Turchetto L., Lo Cicero V., Soncin S., Muzzarelli S., Auricchio A., Moccett, T. Combined Delivery of Bone Marrow-Derived Mononuclear Cells in Chronic Ischemic Heart Disease: Rationale and Study Design. *Clin. Cardiol, 2013, Vol. 36, no. 8, pp. 435-441.* | *-* |  |